ArticleThoracic cancer2018
Stereotactic body radiotherapy for central lung tumors: Finding the balance between safety and efficacy in the "no fly" zone.
Article in Thoracic cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05291780 (STereotactic Ablative RadioTherapy in NEWly Diagnosed and Recurrent Locally Advanced Non-small Cell Lung Canter Patients Unfit for concurrEnt RAdio-chemotherapy), which is not on this map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
STereotactic Ablative RadioTherapy in NEWly Diagnosed and Recurrent Locally Advanced Non-small Cell Lung Canter Patients Unfit for concurrEnt RAdio-chemotherapy
Who cites it
7 citing papers in PubMed.
- Article
- Comparison of dosimetric parameters and delivery accuracy between conformal radiotherapy-intensity modulated radiotherapy-combined and intensity-modulated radiotherapy planning for central lung cancer patients receiving stereotactic body radiotherapy.Quantitative imaging in medicine and surgery · 2026Article
- Stage I and II nonsmall cell lung cancer treatment options.Breathe (Sheffield, England) · 2024Review
- Plan quality analysis of stereotactic ablative body radiotherapy treatment planning in liver tumor.Journal of applied clinical medical physics · 2023Article
- Stereotactic body radiation therapy versus fractionated radiation therapy for early-stage bronchopulmonary carcinoid.Lung cancer management · 2019Article
- Stereotactic body radiation therapy in early-stage NSCLC: historical review, contemporary evidence and future implications.Lung cancer management · 2019Review
- Evidence-Based Planning Target Volume Margin Reduction for Modern Lung Stereotactic Ablative Radiation Therapy Using Deformable Registration.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStereotactic body radiotherapy (SBRT) has emerged as a highly effective technique to treat medically inoperable non-small cell lung cancer (NSCLC). Doses must be chosen carefully when treating central lesions because of the potential for significant toxicity. This study reviews the outcomes of a cohort of patients with central lung tumors treated with SBRT.
methodsWe identified 18 patients (12 women, 6 men) with central lesions that were treated with SBRT at our institution. Overall survival and local, regional, and distant control rates were assessed by Kaplan-Meier methodology. Correlations with outcomes were determined by multivariate analysis via Cox regression models.
resultsEighty-nine percent of patients had a pathological diagnosis of NSCLC. The median dose to the planning target volume was 40 Gy (range: 30-50) in five fractions, yielding a median biologic equivalent dose (BED
conclusionsLung SBRT to central lesions is safe and effective when using five fraction regimens. BED
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.